At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Amicus Therapeutics is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
More...
NEWS
10/19/2014 Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011
09/30/2014 Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable
08/20/2014 Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
More...

U.S. NEWS
Agonizing Choices for Lives Saved by Miracle Drugs
By GEETA ANAND

Seven months ago, Megan Crowley made a gutsy decision: to undergo a radical surgery to  straighten out her spine, which has been crippled by Pompe disease. Photo: Lexey Swall
Click Here to Read the Article
Click Here to View the Video

Copyright © 2014 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy